B. Riley Analysts Decrease Earnings Estimates for Aspen Aerogels, Inc. (NYSE:ASPN)

Aspen Aerogels, Inc. (NYSE:ASPN) – Research analysts at B. Riley dropped their FY2026 earnings per share (EPS) estimates for shares of Aspen Aerogels in a report issued on Thursday, August 15th. B. Riley analyst R. Pfingst now expects that the construction company will earn $1.04 per share for the year, down from their previous forecast of $1.15. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Aspen Aerogels’ current full-year earnings is $0.12 per share. B. Riley also issued estimates for Aspen Aerogels’ FY2027 earnings at $1.86 EPS.

Other analysts also recently issued reports about the stock. Roth Mkm restated a “buy” rating and set a $36.00 price objective (up from $28.00) on shares of Aspen Aerogels in a research report on Wednesday, June 12th. HC Wainwright boosted their price objective on Aspen Aerogels from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Canaccord Genuity Group increased their target price on Aspen Aerogels from $18.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. Craig Hallum boosted their price target on Aspen Aerogels from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Friday, June 14th. Finally, Benchmark reaffirmed a “buy” rating and set a $14.00 price objective on shares of Aspen Aerogels in a report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.20.

Aspen Aerogels Price Performance

NYSE:ASPN traded up $1.85 during trading hours on Friday, hitting $26.26. 595,163 shares of the stock traded hands, compared to its average volume of 1,224,125. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -58.41 and a beta of 2.15. Aspen Aerogels has a 1 year low of $5.32 and a 1 year high of $31.74. The stock has a 50 day moving average price of $24.54 and a 200 day moving average price of $20.93. The company has a quick ratio of 3.29, a current ratio of 4.01 and a debt-to-equity ratio of 0.24.

Aspen Aerogels (NYSE:ASPN) last posted its quarterly earnings data on Wednesday, August 7th. The construction company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.05 by $0.16. The firm had revenue of $117.80 million for the quarter, compared to the consensus estimate of $101.99 million. Aspen Aerogels had a negative return on equity of 6.35% and a negative net margin of 10.73%. The business’s revenue for the quarter was up 144.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.22) earnings per share.

Insider Activity at Aspen Aerogels

In related news, CEO Donald R. Young sold 256,944 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $29.24, for a total value of $7,513,042.56. Following the completion of the sale, the chief executive officer now directly owns 502,855 shares in the company, valued at $14,703,480.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 4.30% of the stock is owned by insiders.

Institutional Trading of Aspen Aerogels

Several institutional investors and hedge funds have recently made changes to their positions in the business. Banque Cantonale Vaudoise lifted its stake in Aspen Aerogels by 37.5% in the first quarter. Banque Cantonale Vaudoise now owns 4,593 shares of the construction company’s stock worth $81,000 after acquiring an additional 1,252 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Aspen Aerogels by 10.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,310 shares of the construction company’s stock worth $341,000 after purchasing an additional 1,339 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Aspen Aerogels by 15.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,580 shares of the construction company’s stock worth $257,000 after buying an additional 1,938 shares during the period. Thompson Davis & CO. Inc. increased its holdings in shares of Aspen Aerogels by 14.7% in the 4th quarter. Thompson Davis & CO. Inc. now owns 24,150 shares of the construction company’s stock valued at $381,000 after acquiring an additional 3,100 shares during the period. Finally, Point72 Hong Kong Ltd bought a new position in shares of Aspen Aerogels in the 2nd quarter worth $84,000. 97.64% of the stock is currently owned by institutional investors.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.